PMCB PharmaCyte Biotech Total Debt to Capital

Serving as the primary valuation tool, this price chart demonstrates a debt-to-equity ratio of 0.00 for PharmaCyte Biotech (PMCB). The PharmaCyte Biotech (PMCB) business focuses on developing the Cell-in-a-Box system for targeted treatment of pancreatic neoplasms to reduce therapy toxicity. The team consists of academic specialists retained through equity stakes and research autonomy. A stable roster of experts ensures the continuity of complex medical developments.

For PharmaCyte Biotech (PMCB), with its full outsourcing model for clinical trials and production on GURU.Markets, monitoring the debt-to-equity ratio is critical. This coefficient is calculated as the ratio of total liabilities to net equity, allowing investors to assess the company's degree of financial autonomy and the risks of over-leverage in the absence of in-house production facilities.